LENZ Therapeutics (LENZ) Treasury Shares (2020 - 2025)

LENZ Therapeutics (LENZ) posted quarterly Treasury Shares of $27640.0 for Q4 2025, down 99.87% quarter-over-quarter from $22.0 million in Q4 2023.

LENZ Therapeutics (LENZ) Treasury Shares (2020 - 2025) Analysis & Trends

LENZ Therapeutics (LENZ) has reported Treasury Shares for 5 consecutive years, with $27640.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Treasury Shares changed N/A year-over-year to $27640.0; the TTM figure through Dec 2025 stood at $27640.0 (changed N/A YoY), while the FY2025 annual figure was $27640.0, changed N/A from the prior year.
Treasury Shares retreated to $27640.0 in Q4 2025 per LENZ's latest filing, from $22.0 million in the prior quarter.
Across five years, Treasury Shares topped out at $29.8 million in Q1 2021 and bottomed at $27640.0 in Q4 2025.
Historically, Treasury Shares has averaged $18.1 million across 4 years, with a median of $22.0 million in 2023.
On a YoY basis, Treasury Shares climbed as much as 644.85% in 2023 and fell as far as 644.85% in 2023.
LENZ Therapeutics' Treasury Shares stood at $29.8 million in 2021, then sank by 90.1% to $3.0 million in 2022, then surged by 644.85% to $22.0 million in 2023, then tumbled by 99.87% to $27640.0 in 2025.
Business Quant data shows LENZ's Treasury Shares at $27640.0 in Q4 2025, $22.0 million in Q4 2023, and $22.0 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	LENZ Therapeutics	147.30 Mn	147.30 Mn	5.21 Mn	-

Download Data